Literature DB >> 7561751

Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays.

G J Inman1, P J Farrell.   

Abstract

The EBNA-LP protein (also known as EBNA-5) of Epstein-Barr virus (EBV) has been reported previously to colocalize in the nuclei of cells with the pRb protein and to bind in vitro to pRb and to the p53 protein, suggesting a role for EBNA-LP in modulation of the function of these proteins. Here we test in transfection assays whether EBNA-LP expression has any functional consequence for repression of E2F-1 activity by pRb or p107 or for activation of transcription by the p53 protein. No significant effect could be found, although the assay systems were sensitive to the established effects of simian virus 40 large T antigen and human papillo-mavirus type 16 E6 protein. There was very effective repression of GAL4/E2F-1 transactivation by p107, consistent with earlier reports and indicating that p107 can interact with the E2F-1 transactivation domain, even though p107 has been reported to bind specifically to E2F complexes containing E2F-4. The results indicate that, if the associations of EBNA-LP with pRB and p53 are physiologically relevant, they most likely affect other functions of these proteins or modulate their gene regulatory functions in ways that cannot be detected by transfection into cycling transformed cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561751     DOI: 10.1099/0022-1317-76-9-2141

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  15 in total

1.  Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function.

Authors:  L R Bonin; J K McDougall
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2.

Authors:  R Peng; J Tan; P D Ling
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.

Authors:  R Peng; A V Gordadze; E M Fuentes Pananá; F Wang; J Zong; G S Hayward; J Tan; P D Ling
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  Molecular virology of Epstein-Barr virus.

Authors:  G W Bornkamm; W Hammerschmidt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  EBNA-LP associates with cellular proteins including DNA-PK and HA95.

Authors:  I Han; S Harada; D Weaver; Y Xue; W Lane; S Orstavik; B Skalhegg; E Kieff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Cell cycle stage-specific phosphorylation of the Epstein-Barr virus immortalization protein EBNA-LP.

Authors:  M K Kitay; D T Rowe
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle.

Authors:  V L Zacny; J Wilson; J S Pagano
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  Identification of major phosphorylation sites of Epstein-Barr virus nuclear antigen leader protein (EBNA-LP): ability of EBNA-LP to induce latent membrane protein 1 cooperatively with EBNA-2 is regulated by phosphorylation.

Authors:  A Yokoyama; M Tanaka; G Matsuda; K Kato; M Kanamori; H Kawasaki; H Hirano; I Kitabayashi; M Ohki; K Hirai; Y Kawaguchi
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity.

Authors:  Jason S Knight; Erle S Robertson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 10.  Nucleoside diphosphate kinase/Nm23 and Epstein-Barr virus.

Authors:  Masanao Murakami; Rajeev Kaul; Pankaj Kumar; Erle S Robertson
Journal:  Mol Cell Biochem       Date:  2009-05-03       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.